Provided By GlobeNewswire
Last update: Sep 13, 2024
CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Thursday, September 12, 2024.
NASDAQ:XRTX (10/14/2025, 8:00:03 PM)
0.8748
0 (-0.39%)
Find more stocks in the Stock Screener